- Home
- AVY vs GMAB Comparison
AVY vs GMAB Comparison
Compare AVY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVY
- GMAB
- Stock Information
- Founded
- AVY 1935
- GMAB 1999
- Country
- AVY United States
- GMAB Denmark
- Employees
- AVY N/A
- GMAB N/A
- Industry
- AVY Containers/Packaging
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AVY Consumer Discretionary
- GMAB Health Care
- Exchange
- AVY Nasdaq
- GMAB Nasdaq
- Market Cap
- AVY 13.1B
- GMAB 15.4B
- IPO Year
- AVY N/A
- GMAB N/A
- Fundamental
- Price
- AVY $165.66
- GMAB $27.82
- Analyst Decision
- AVY Buy
- GMAB Buy
- Analyst Count
- AVY 10
- GMAB 6
- Target Price
- AVY $197.00
- GMAB $37.60
- AVG Volume (30 Days)
- AVY 546.7K
- GMAB 1.4M
- Earning Date
- AVY 10-22-2025
- GMAB 11-05-2025
- Dividend Yield
- AVY 2.27%
- GMAB N/A
- EPS Growth
- AVY 14.63
- GMAB 77.72
- EPS
- AVY 8.92
- GMAB 21.62
- Revenue
- AVY $8,737,900,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- AVY $2.20
- GMAB $22.68
- Revenue Next Year
- AVY $3.95
- GMAB $15.85
- P/E Ratio
- AVY $18.57
- GMAB $1.29
- Revenue Growth
- AVY 1.66
- GMAB 32.97
- 52 Week Low
- AVY $157.00
- GMAB $17.24
- 52 Week High
- AVY $224.38
- GMAB $28.75
- Technical
- Relative Strength Index (RSI)
- AVY 39.51
- GMAB 70.96
- Support Level
- AVY $164.30
- GMAB $27.58
- Resistance Level
- AVY $168.86
- GMAB $28.75
- Average True Range (ATR)
- AVY 2.83
- GMAB 0.39
- MACD
- AVY -0.46
- GMAB 0.19
- Stochastic Oscillator
- AVY 9.64
- GMAB 79.28
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.